Search

GlaxoSmithKline PLC

Closed

SectorHealthcare

1,400.5 -1.41

Overview

Share price change

24h

Current

Min

1395

Max

1401

Key metrics

By Trading Economics

Income

1.3B

1.8B

Sales

-601M

7.5B

P/E

Sector Avg

18.395

40.048

EPS

44.9

Dividend yield

4.45

Profit margin

23.576

Employees

68,629

EBITDA

2B

3.1B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+13.44% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.45%

2.45%

Next Earnings

29 Oct 2025

Next Dividend date

9 Oct 2025

Next Ex Dividend date

14 Aug 2025

Market Stats

By TradingEconomics

Market Cap

848K

57B

Previous open

1401.91

Previous close

1400.5

News Sentiment

By Acuity

31%

69%

164 / 375 Healthcare

GlaxoSmithKline PLC Chart

Past performance is not a reliable indicator of future results.

Related News

30 Jul 2025, 06:50 UTC

Earnings

GSK Upbeat on Guidance After Specialty Medicines Boost Sales

18 Jul 2025, 09:39 UTC

Major Market Movers

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

2 Jun 2025, 10:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

14 May 2025, 11:01 UTC

Acquisitions, Mergers, Takeovers

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14 May 2025, 06:39 UTC

Acquisitions, Mergers, Takeovers

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12 May 2025, 09:36 UTC

Major Market Movers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 Jul 2025, 09:08 UTC

Market Talk
Earnings

GSK Results Look Solid, But Benefit From Temporary Effects -- Market Talk

30 Jul 2025, 06:06 UTC

Earnings

Correct: GSK PLC 2Q EPS 35.5p

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q EPS 35.5p

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q Pretax Pft GBP1.89B

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q Net Pft GBP1.44B

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q Adj EPS 46.5p

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q Turnover GBP7.99B

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q Pre-items, Pretax Pft GBP2.5B

30 Jul 2025, 06:00 UTC

Earnings

GSK PLC 2Q Oper Pft GBP2.02B

28 Jul 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

18 Jul 2025, 09:05 UTC

Hot Stocks

Stocks to Watch Friday: Netflix, Norfolk Southern, Amex -- WSJ

7 Jul 2025, 15:00 UTC

Acquisitions, Mergers, Takeovers

GSK Completes Acquisition of Efimosfermin

2 Jun 2025, 10:00 UTC

Acquisitions, Mergers, Takeovers

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

15 May 2025, 15:20 UTC

Top News

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14 May 2025, 06:08 UTC

Acquisitions, Mergers, Takeovers

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14 May 2025, 06:03 UTC

Acquisitions, Mergers, Takeovers

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14 May 2025, 06:03 UTC

Acquisitions, Mergers, Takeovers

GSK PLC to Pay $1.2B Upfront

14 May 2025, 06:03 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy Efimosfermin for up to $2B

14 May 2025, 06:00 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy Efimosfermin

12 May 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 May 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30 Apr 2025, 08:54 UTC

Market Talk
Earnings

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30 Apr 2025, 07:49 UTC

Market Talk
Earnings

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30 Apr 2025, 07:06 UTC

Market Talk
Earnings

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

GlaxoSmithKline PLC Forecast

Price Target

By TipRanks

13.44% upside

12 Months Forecast

Average 1,584.25 GBX  13.44%

High 2,290 GBX

Low 1,290 GBX

Based on 13 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

13 ratings

2

Buy

8

Hold

3

Sell

Sentiment

By Acuity

164 / 375 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.